Molecular basis of the VHL hereditary cancer syndrome
The DOI matches its Crossref record; 145 of the 146 references it cites were found in a registry or an index.
Abstract
The von Hippel-Lindau hereditary cancer syndrome was first described about 100 years ago. The unusual clinical features of this disorder predicted a role for the von Hippel-Lindau gene (VHL) in the oxygen-sensing pathway. Indeed, recent studies of this gene have helped to decipher how cells sense changes in oxygen availability, and have revealed a previously unappreciated role of prolyl hydroxylation in intracellular signalling. These studies, in turn, are laying the foundation for the treatment of a diverse set of disorders, including cancer, myocardial infarction and stroke.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the PHDs utilize ␣-ketoglutarate as a cosubstrate and require ferrous iron (Fe 2ϩ ) and ascorbate as cofactors (Kaelin, 2002;Schofield and Zhang, 1999).”
From Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase (2005) · cites this paper as Kaelin, 2002
In the citing paper
“Since pVHL binding to the ODD domain is dependent on PHD activity (Kaelin, 2002;Safran and Kaelin, 2003)”
From Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase (2005) · cites this paper as Kaelin, 2002
Citations
Cites
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735 · cited 1×
“The interaction of pVHL with HIF-α is governed by the enzymatic hydroxylation of conserved proline residues that are located within highly conserved, peptidic, pVHL-binding domains within the HIF-α subunit”
BackgroundEpstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene
Latif, F., Tory, K., Gnarra, J., Yao, M., Duh, F.-M., Orcutt, M. L., Stackhouse, T., Kuzmin, I., Modi, W., Geil, L., et al. (1993) · Science · doi:10.1126/science.8493574 · Cited by 2,973
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Regulation of Mammalian O 2 Homeostasis by Hypoxia-Inducible Factor 1
Semenza, G. L. (1999) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.15.1.551 · Cited by 1,914
Mutations of the VHL tumour suppressor gene in renal carcinoma
Gnarra, J. R., Tory, K., Weng, Y., Schmidt, L., Wei, M. H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.-M., et al. (1994) · Nature Genetics · doi:10.1038/ng0594-85 · Cited by 1,730
HIF‐1α is required for solid tumor formation and embryonic vascularization
Ryan, H. E., Lo, J., & Johnson, R. S. (1998) · The EMBO Journal · doi:10.1093/emboj/17.11.3005 · Cited by 1,579
Ohh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G. (2000) · Nature Cell Biology · doi:10.1038/35017054 · Cited by 1,577
Self-citation
Research works printed but not linked: 5
- Collins, E. T. Intra-ocular growths (two cases, brother and sister, with peculiar vascular new growth, probably retinal, affecting both eyes). Trans. Ophthalmol. Soc. UK 14, 141–149 (1894).
- Clifford, S., Prowse, A., Affara, N., Buys, C. & Maher, E. Inactivation of the von Hippel–Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosom. Cancer 22, 200–209 (1998). · DOI · Paper page
- Gallou, C. et al. Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC. Hum. Mutat. 13, 464–475 (1999). · DOI
- Ivan, M. et al. Biochemical purification and pharmacological inhibition of a mammalian HIF prolyl hydroxylase. Proc. Natl Acad. Sci. USA (in the press).
- Aiello, L. et al. Rapid and durable recovery of visual function in a patient with von Hippel–Lindau syndrome and optic nerve head hemangioma following systemic treatment with the VEGF receptor inhibitor SU5416. Ophthalmology (in the press).
Cited by
Items 401–500 of 864
Domingos, P. L. B., de Souza, M. G., Guimarães, T. A., Santos, E. S., Farias, L. C., Fraga, C. A. D. C., Jones, K. M., Santos, S. H. S., de Paula, A. M. B., & Guimarães, A. L. S. (2017) · Pathology - Research and Practice · doi:10.1016/j.prp.2017.02.003 · Cited by 26
Cuesta, Á. M., Albiñana, V., Gallardo‐Vara, E., Recio-Poveda, L., de Rojas-P, I., Heras, K. V. G. D. L., Aguirre, D., & Botella, L. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-46448-6 · Cited by 30
Vogel, T. W. A., Brouwers, F. M., Lubensky, I. A., Vortmeyer, A. O., Weil, R. J., Walther, M. M., Oldfield, E. H., Linehan, W. M., Pacák, K., & Zhuang, Z. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1899 · Cited by 29
Yamamoto, S., Tsuda, H., Suzuki, K., Takano, M., Tamai, S., & Matsubara, O. (2009) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-009-0816-9 · Cited by 27
Heat-shock protein 90 inhibitors in antineoplastic therapy: is it all wrapped up?
Isaacs, J. S. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.6.569 · Cited by 26
Pheochromocytoma-associated syndromes: genes, proteins and functions of RET, VHL and SDHx
Gimm, O. (2005) · Familial Cancer · doi:10.1007/s10689-004-5740-1 · Cited by 26
Consensus Guidelines for Ocular Surveillance of von Hippel-Lindau Disease
Daniels, A. B., Chang, E. Y., Chew, E. Y., Gombos, D. S., Gorin, M. B., Shields, C. L., & Wiley, H. E. (2024) · Ophthalmology · doi:10.1016/j.ophtha.2023.12.014 · Cited by 26
Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma
Joshi, S., Singh, A. R., & Durden, D. L. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2639-x · Cited by 25
Combined deletion of Vhl, Trp53 and Kif3a causes cystic and neoplastic renal lesions
Guinot, A., Lehmann, H., Wild, P. J., & Frew, I. J. (2016) · The Journal of Pathology · doi:10.1002/path.4736 · Cited by 28
Cancer of the Central Nervous System
Dorsey, J. F., Salinas, R. D., Dang, M. T., Alonso‐Basanta, M., Judy, K. D., Maity, A. M., Lustig, R. A., Lee, J. Y. K., Phillips∥, P. C., & Pruitt, A. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00063-3 · Cited by 33
von Hippel–Lindau protein promotes Skp2 destabilization on DNA damage
Roe, J., Kim, H. R., Hwang, I.-Y., Cho, E., & Youn, H.-D. (2011) · Oncogene · doi:10.1038/onc.2011.40 · Cited by 25
Pheochromocytoma: implications in tumorigenesis and the actual management.
Shah, U. A., Giubellino, A., & Pacák, K. (2012) · PubMed · Cited by 30
Intersections between mitochondrial sirtuin signaling and tumor cell metabolism
Herrera, K. N. G., Lee, J. J., & Haigis, M. C. (2015) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2015.1031879 · Cited by 28
Wacker, I., Sachs, M., Knaup, K. X., Wiesener, M. S., Weiske, J., Huber, O., Akçetin, Z., & Behrens, J. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01184-07 · Cited by 30
Jiang, W., Dulaimi, E., Devarajan, K., Parsons, T., Wang, Q., Liao, L., Cho, E.-A., O’Neill, R., Solomides, C., Peiper, S. C., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164554 · Cited by 26
Shuin, T., Yamazaki, I., Tamura, K., Kamada, M., & Ashida, S. (2004) · International Journal of Clinical Oncology · doi:10.1007/s10147-004-0415-3 · Cited by 24
Miyakis, S., Liloglou, T., Kearney, S., Xinarianos, G., Spandidos, D. A., & Field, J. K. (2003) · Lung Cancer · doi:10.1016/s0169-5002(02)00506-8 · Cited by 24
Min, B., Park, H. J., Lee, S., Li, Y., Choi, J.-M., Lee, J. Y., Kim, J., Choi, Y. D., Kwon, Y.-G., Lee, H., et al. (2015) · Oncogene · doi:10.1038/onc.2015.439 · Cited by 24
Tuberous sclerosis—A model for tumour growth
Dodd, K. M., & Dunlop, E. A. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.01.025 · Cited by 24
A Concise Review of the Multimodality Imaging Features of Renal Cell Carcinoma
Morshid, A. I., Duran, E., Choi, W. J., & Duran, C. (2021) · Cureus · doi:10.7759/cureus.13231 · Cited by 23
Gotö, Y., Koyasu, S., Kobayashi, M., & Harada, H. (2017) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2017.07.007 · Cited by 26
Von Hippel-Lindau tumor suppressor pathways & corresponding therapeutics in kidney cancer
Shulman, M., Shi, R., & Zhang, Q. H. (2021) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2021.05.016 · Cited by 25
Siroky, B. J., Czyzyk-Krzeska, M., & Bissler, J. J. (2009) · Nature Reviews Nephrology · doi:10.1038/ncpneph1032 · Cited by 26
Su, Y., Liu, J., Tian, Y., Dong, H., Shi, M., Zhang, J., Li, W., Huang, Q., Xiang, N., Wang, C., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116427 · Cited by 25
Targeting HIF2α Translation with Tempol in VHL-Deficient Clear Cell Renal Cell Carcinoma
Sourbier, C., Srivastava, G. K., Ghosh, M. C., Ghosh, S., Yang, Y., Gupta, G. N., DeGraff, W., Krishna, M. C., Mitchell, J. B., Rouault, T. A., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.561 · Cited by 23
Anti-angiogenesis approach to genitourinary cancer treatment
Aragon‐Ching, J. B., & Dahut, W. L. (2009) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2009.05.002 · Cited by 22
Vascular endothelial growth factor inhibition: Conflicting roles in tumor growth
Saranadasa, M., & Wang, E. S. (2010) · Cytokine · doi:10.1016/j.cyto.2010.06.012 · Cited by 24
Pantuck, A., THOMAS, G. V., Belldegrun, A. S., & Figlin, R. A. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.06.002 · Cited by 23
von Hippel-Lindau disease: recent advances and therapeutic perspectives
Richard, S. (2003) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.3.2.215 · Cited by 26
Briganti, V., Cuccurullo, V., Stasio, G. D. D., & Mansi, L. (2019) · Current Radiopharmaceuticals · doi:10.2174/1874471012666190301122524 · Cited by 22
Ubiquitin-specific protease 20 in human disease: Emerging role and therapeutic implications
Qin, B., Zhou, L., Wang, F., & Wang, Y. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115352 · Cited by 21
Hasani‐Ranjbar, S., Amoli, M. M., Ebrahim‐Habibi, A., Haghpanah, V., Hejazi, M., Soltani, A., & Larijani, B. A. (2009) · Familial Cancer · doi:10.1007/s10689-009-9266-4 · Cited by 24
Patient-based strategy for systemic treatment of metastatic renal cell carcinoma
Kirchner, H. H., Strumberg, D., Bahl, A. K., & Overkamp, F. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.25 · Cited by 21
Mysore, V. S., Szablowski, J. O., Dervan, P. B., & Frost, P. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0361 · Cited by 24
Collagen XIII-derived ectodomain regulates bone angiogenesis and intracortical remodeling
Koivunen, J. T., Kemppainen, A. V., Finnilä, M., Keski‐Filppula, R., Härönen, H., Tu, H., Pellikka, H., Heikkinen, A., Kylmäoja, E., Sormunen, R. T., et al. (2019) · Matrix Biology · doi:10.1016/j.matbio.2019.06.005 · Cited by 24
Murase, S. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.470583 · Cited by 22
Mutational status of VHL gene and its clinical importance in renal clear cell carcinoma
Alves, M. R., Carneiro, F. C., Lavorato-Rocha, A. M., da Costa, W. H., da Cunha, I. W., Zéqui, S. D. C., Guimarães, G. C., Soares, F. A., Carraro, D. M., & Rocha, R. M. (2014) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-014-1629-z · Cited by 24
Knickelbein, J. E., Jacobs-El, N., Wong, W. T., Wiley, H. E., Cukras, C. A., MEYERLE, C. B., & Chew, E. Y. (2016) · Ophthalmology Retina · doi:10.1016/j.oret.2016.10.007 · Cited by 21
Von Hippel Lindau tumor suppressor controls m6A-dependent gene expression in renal tumorigenesis
Zhang, C., Yu, M., Hepperla, A. J., Zhang, Z., Raj, R., Zhong, H., Zhou, J. R., Hu, L., Fang, J. Q., Liu, H., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci175703 · Cited by 23
Lu, S., Lu, K. N., Cheng, S., Hu, B., Ma, X., Nystrom, N. A., & Lu, X. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004257 · Cited by 20
Belzutifan: a novel therapy for von Hippel–Lindau disease
Zhou, J., & Gong, K. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00544-5 · Cited by 22
The Role of Propranolol as a Repurposed Drug in Rare Vascular Diseases
Cuesta, Á. M., Gallardo‐Vara, E., Casado‐Vela, J., Recio-Poveda, L., Botella, L. M., & Albiñana, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084217 · Cited by 30
RSUME inhibits VHL and regulates its tumor suppressor function
Gerez, J., Tedesco, L., Bonfiglio, J. J., Fuertes, M., Barontini, M., Silberstein, S., Wu, Y., Renner, U., Páez-Pereda, M., Holsboer, F., et al. (2014) · Oncogene · doi:10.1038/onc.2014.407 · Cited by 24
Khacho, M., Mekhail, K., Pilon‐Larose, K., Payette, J., & Lee, S. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01044-07 · Cited by 28
Small activating RNA induced expression of VHL gene in renal cell carcinoma.
Kang, M., Park, K. H., Lee, C. W., Lee, M. Y., Han, S., Li, L.-C., & Kang, J. (2018) · International Journal of Biochemistry and Cell Biology · doi:10.1016/j.biocel.2018.02.002 · Cited by 19
Von Hippel-Lindau syndrome: molecular mechanisms of the disease
Calzada, M. J. (2010) · Clinical & Translational Oncology · doi:10.1007/s12094-010-0485-9 · Cited by 23
Somatic gain-of-function HIF2A mutations in sporadic central nervous system hemangioblastomas
Taïeb, D., Barlier, A., Yang, C., Pertuit, M., Tchoghandjian, A., Rochette, C., Zattara-Canoni, H., Figarella‐Branger, D., Zhuang, Z., Pacák, K., et al. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1983-y · Cited by 21
Takada, M., Zhuang, M., Inuzuka, H., Zhang, J., Zurlo, G., Zhang, J., & Zhang, Q. H. (2016) · Oncotarget · doi:10.18632/oncotarget.14290 · Cited by 21
Genetic basis of kidney cancer: a model for developing molecular‐targeted therapies
Vira, M. A., Novakovic, K. R., Pinto, P. A., & Linehan, W. M. (2007) · British Journal of Urology · doi:10.1111/j.1464-410x.2007.06814.x · Cited by 20
Predictors of Response to Targeted Therapy in Renal Cell Carcinoma
Eisengart, L. J., MacVicar, G. R., & Yang, X. J. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2010-0308-ra · Cited by 18
Zhao, Z., Chen, C., Lin, J., Zeng, W.-T., Zhao, J., Liang, Y., Tan, Q., Yang, C., & Li, H. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5561 · Cited by 21
Integrative analysis of neuroblastoma and pheochromocytoma genomics data
Szabó, P. M., Pintér, M., Szabó, D. R., Zsippai, A., Patócs, A., Falus, A., Rácz, K., & Igaz, P. (2012) · BMC Medical Genomics · doi:10.1186/1755-8794-5-48 · Cited by 24
Genotype–phenotype analysis of von Hippel–Lindau syndrome in fifteen Indian families
Vikkath, N., Govindan, S., Nampoothiri, S., Radhakrishnan, N., Pillai, G. S., Nair, V., Pooleri, G. K., Mathew, G., Menon, K. N., Ariyannur, P. S., et al. (2015) · Familial Cancer · doi:10.1007/s10689-015-9806-z · Cited by 19
The growing family of hereditary renal cell carcinoma
Richard, S., Lidereau, R., & Giraud, S. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh535 · Cited by 18
Woldemichael, G. M., Turbyville, T. J., Linehan, W. M., & McMahon, J. B. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-0757 · Cited by 18
mTOR inhibitors in advanced renal cell carcinomas: From biology to clinical practice
Barthélémy, P., Hoch, B., Chevreau, C., Joly, F., Laguerre, B., Lokiec, F. M., & Duclos, B. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.02.006 · Cited by 21
Germline mutations in the von Hippel–Lindau disease (VHL) gene in mainland Chinese families
Zhang, J., Huang, Y., Pan, J., Liu, D., Zhou, L., Xue, W., Chen, Q., Dong, B., & Xuan, H. (2008) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-008-0399-x · Cited by 18
Ku, J. H., Park, Y. H., Myung, J. K., Moon, K. C., Kwak, C. H., & Kim, H. H. (2009) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2009.08.007 · Cited by 18
Albiñana, V., Gallardo‐Vara, E., de Rojas-P, I., Recio-Poveda, L., Aguado, T., Canto-Cano, A., Aguirre, D. T., Serra, M. M., González‐Peramato, P., Martínez‐Piñeiro, L., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092740 · Cited by 20
Rossini, L., Durante, C., Bresolin, S., Opocher, E., Marzollo, A., & Biffi, A. (2022) · Cancers · doi:10.3390/cancers14153741 · Cited by 22
Feijoo‐Cuaresma, M., Méndez, F., Maqueda, A., Esteban, M. A., Naranjo‐Suarez, S., Castellanos, M. C., del Cerro, M. H., Vazquez, S. N., García-Pardo, A., Landázuri, M. O., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709390200 · Cited by 28
Li, Q., Zhang, Z., Fan, Y., & Zhang, Q. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2020.562868 · Cited by 19
Molecular Genetics of Renal Cell Carcinoma: A Narrative Review Focused on Clinical Relevance
Millan, B., Loebach, L., Blachman-Braun, R., Patel, M. H., Saini, J., Linehan, W. M., & Ball, M. W. (2025) · Current Oncology · doi:10.3390/curroncol32060359 · Cited by 20
Targeted therapy and hand–foot skin reaction in advanced renal cell carcinoma
Yang, C., Chuang, C., Hsieh, J., & Chang, J. W. (2010) · Expert Opinion on Drug Safety · doi:10.1517/14740331003596349 · Cited by 17
Renal carcinogenesis--insights into signaling pathways.
Cojocaru, E., Lozneanu, L., Giuşcă, S. E., Căruntu, I.-D., & Danciu, M. (2015) · PubMed · Cited by 19
Karimi, S., Nikkhah, H., Ahmadieh, H., & Safi, S. (2018) · Retinal Cases & Brief Reports · doi:10.1097/icb.0000000000000718 · Cited by 20
Viral Manipulations of the Cullin-RING Ubiquitin Ligases
Liu, Y., & Tan, X. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-1025-0_7 · Cited by 17
The role of hypoxia inducible factor-1 in cell metabolism – a possible target in cancer therapy
Aiba, R. S. B., Dimova, E. Y., Görlach, A., & Kietzmann, T. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.10.4.583 · Cited by 19
Von Hippel-Lindau syndrome: clinical features, genetic foundations, and management strategies
Harbi, E., & Aschner, M. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10403-8 · Cited by 18
Bauer, T., Eils, R., & König, R. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr366 · Cited by 16
Wang, H., Lin, G., Zhou, J., Zong, Y., Ning, X., Wang, T., Yin, S., Zhang, K., & Ji, J. (2022) · Aquaculture · doi:10.1016/j.aquaculture.2022.738859 · Cited by 16
Transgenic Models to Understand Hypoxia‐Inducible Factor Function
Doedens, A. L., & Johnson, R. S. (2007) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(07)35005-2 · Cited by 19
Targeted therapies in metastatic renal cancer in 2009
Bastien, L., Culine, S., Paule, B., Ledbai, S., Patard, J., & TAILLE, A. D. L. (2009) · British Journal of Urology · doi:10.1111/j.1464-410x.2009.08454.x · Cited by 17
Liprin-α4 is a new hypoxia-inducible target gene required for maintenance of cell–cell contacts
Mattauch, S., Sachs, M., & Behrens, J. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.06.022 · Cited by 17
Gharbi, H., Fabretti, F., Bharill, P., Rinschen, M. M., Brinkkoetter, S., Frommolt, P., Burst, V. R., Schermer, B., Benzing, T. R., & Müller, R. (2013) · Aging Cell · doi:10.1111/acel.12081 · Cited by 16
Prasad, R., Johnston, L., Savage, M. O., Martin, L., Perry, L. A., & Storr, H. L. (2010) · Journal of Endocrinological Investigation · doi:10.1007/bf03347089 · Cited by 16
Homotypic association between tumour-associated VHL proteins leads to the restoration of HIF pathway
Chung, J., Roberts, A. M., Chow, J., Coady-Osberg, N., & Ohh, M. (2005) · Oncogene · doi:10.1038/sj.onc.1209328 · Cited by 18
A patient with bilateral pheochromocytoma as part of a Von Hippel-Lindau (VHL) syndrome type 2C
Schreinemakers, J. M. J., Zonnenberg, B. A., Höppener, J. W. M., Hes, F. J., Rinkes, I. H. M. B., & Lips, C. J. M. (2007) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-5-112 · Cited by 18
Von Hippel-Lindau Disease: A New Approach to an Old Problem
Tootee, A., & Ranjbar, S. H. (2012) · Intern J Endocrinol Metab · doi:10.5812/ijem.4510 · Cited by 16
Cinque, A., Minnei, R., Floris, M., & Trevisani, F. (2022) · Cancers · doi:10.3390/cancers14215352 · Cited by 18
Wang, X., Chen, C., Vuong, D., Rodríguez, S., Lam, V., Roleder, C., Wang, J. H., Kambhampati, S., Berger, A., Pennock, N. D., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01889-x · Cited by 17
Neurocutaneous Diseases: Diagnosis, Management, and Treatment
Kioutchoukova, I. P., Foster, D. T., Thakkar, R. N., Ciesla, C. D., Cabassa, J. S., Strouse, J., Kurz, H., & Lucke-Wold, B. P. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061648 · Cited by 21
Molecular basis for the treatment of renal cell carcinoma
Suárez, C., Morales‐Barrera, R., Muñoz‐Couselo, E., Rodon, J. A., Valverde, C. M., & Carles, J. (2010) · Clinical & Translational Oncology · doi:10.1007/s12094-010-0461-4 · Cited by 17
Morphological clues to the appropriate recognition of hereditary renal neoplasms
Moch, H., Ohashi, R., Gandhi, J. S., & Amin, M. B. (2018) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2018.01.005 · Cited by 17
Chen, W., Cheng, X., Wang, X., Wang, J., Wen, X., Xie, C., & Liao, C. (2019) · Oncology Letters · doi:10.3892/ol.2019.9929 · Cited by 20
Criswell, K. A., Cook, J. C., Wojcinski, Z. W., Pegg, D., Herman, J., WESCHE, D. L., Giddings, J. C., Brady, J. T., & Anderson, T. (2012) · Toxicological Sciences · doi:10.1093/toxsci/kfs149 · Cited by 15
Radiologist’s Primer on Imaging of Common Hereditary Cancer Syndromes
Tiwari, R., Singh, A. K., Somwaru, A. S., Menias, C. O., Prasad, S. R., & Katabathina, V. S. (2019) · Radiographics · doi:10.1148/rg.2019180171 · Cited by 17
VHL Synthetic Lethality Signatures Uncovered by Genotype-Specific CRISPR-Cas9 Screens
Sun, N., Petiwala, S. M., Lu, C., Hutti, J. E., Hu, M., Hu, M., Domanus, M. H., Mitra, D., Addo, S. N., Miller, C. P., et al. (2019) · The CRISPR Journal · doi:10.1089/crispr.2019.0018 · Cited by 17
Multifocal Microcysts and Papillary Cystadenoma of the Lung in von Hippel-Lindau Disease
Klein, J., Zhuang, Z., Lubensky, I. A., Colby, T. V., Martínez, F., & Leslie, K. O. (2007) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3180377aaf · Cited by 15
Hikri, E., Shpungin, S., & Nir, U. (2008) · Cellular Signalling · doi:10.1016/j.cellsig.2008.12.011 · Cited by 16
Reconstruction of kidney renal clear cell carcinoma evolution across pathological stages
Pang, S., Sun, Y., Wu, L., Yang, L., Zhao, Y., Wang, Z., & Li, Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-20321-4 · Cited by 15
Genetics, Pathophysiology, and Current Challenges in Von Hippel–Lindau Disease Therapeutics
Gómez-Virgilio, L., Velazquez-Paniagua, M., Cuazozon-Ferrer, L., Silva-Lucero, M.-D.-C., Gutierrez-Malacara, A.-I., Padilla-Mendoza, J.-R., Borbolla-Vázquez, J., Díaz-Hernández, J.-A., Jiménez-Orozco, F.-A., & Cardenas-Aguayo, M.-D.-C. (2024) · Diagnostics · doi:10.3390/diagnostics14171909 · Cited by 18
Transcriptional Regulation of Genes via Hypoxia-Inducible Factor
Roche, O., & Ohh, M. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-376-9_13 · Cited by 14
Vacas, E., Bajo, A. M., Schally, A. V., Sánchez‐Chapado, M., Prieto, J. C., & Carmena, M. J. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.10.021 · Cited by 16
Pilotto, E., Nacci, E. B., Mojà, G. D., Ferrara, A. M., Parrozzani, R., Londei, D., Zovato, S., & Midena, E. (2021) · Scientific Reports · doi:10.1038/s41598-020-79652-w · Cited by 14
Endolymphatic Sac Tumors in von Hippel-Lindau Disease
Codreanu, C. M., Duet, M., Hautefort, C., Wassef, M., Guichard, J., Giraud, S., Richard, S., Gimenez‐Roqueplo, A., & Huy, P. T. B. (2010) · Otology & Neurotology · doi:10.1097/mao.0b013e3181d8d863 · Cited by 14
HIF-1α (1772C>T) polymorphism as marker for breast cancer development
Meka, P. B., Cingeetham, A., Nanchari, S. R., Damineni, S., Tipirisetti, N., Gorre, M., Jarjapu, S., Annamaneni, S., Digumarthi, R., & Satti, V. (2014) · Tumor Biology · doi:10.1007/s13277-014-2949-y · Cited by 14
Park, K.-S., Kim, J. H., Shin, H. W., Chung, K., Im, D., Lim, J. H., & Jung, C. (2015) · BMC Cancer · doi:10.1186/s12885-015-1786-8 · Cited by 16
Taylor, D. G., Ilyas, A., Mehta, G. U., Chen, C., Schiff, D., Oldfield, E. H., & Asthagiri, A. R. (2018) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2018.01.040 · Cited by 14
Cancer of the Central Nervous System
Maity, A. M., Pruitt, A. A., Judy, K. D., Phillips∥, P. C., & Lustig, R. H. (2008) · Elsevier eBooks · doi:10.1016/b978-0-443-06694-8.50074-9 · Cited by 15
Metadata
- Authors
- Kaelin, W. G.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Kaelin, William G.
- ORCID
- Kaelin, William G.
- Venue
- Nature Reviews Cancer
- Published
- 2002-09
- Volume
- 2
- Issue
- 9
- Pages
- 673-682
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2093776019
- Semantic Scholar
- 6b13bcf0623256d5dceb071144a84d45b84f9a99
- Cited by
- 865
- References
- 146
- Citations by year
- 2026: 18 · 2025: 29 · 2024: 25 · 2023: 21 · 2022: 24 · 2021: 25 · 2020: 34 · 2019: 32 · 2018: 28 · 2017: 22 · 2016: 27 · 2015: 29 · 2014: 39 · 2013: 42 · 2012: 46
- FWCI
- 3.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Ear and Head Tumors
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Keywords
- von Hippel-Lindau disease, VHL gene, hereditary cancer, oxygen sensing, prolyl hydroxylation, hypoxia signaling, tumour suppressor, cancer therapy
- MeSH terms
- Animals, von Hippel-Lindau Disease, Humans, Ligases, Neoplasms, Gene Expression Regulation, Neoplastic, Genetic Predisposition to Disease, Tumor Suppressor Proteins, Ubiquitin-Protein Ligases, Von Hippel-Lindau Tumor Suppressor Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.